公开(公告)号：US08748633B2

公开(公告)日：2014-06-10

申请号：US13694063

申请日：2012-10-23

Applicant: Ligand Pharmaceuticals Incorporated

Inventor： Lin Zhi

IPC: C07D207/08

CPC classification number: C07D207/09 ,  A61K31/401 ,  A61K31/402 ,  A61K31/5383 ,  A61K45/06 ,  C07D207/08 ,  C07D207/16 ,  C07D498/04 ,  Y02A50/401

Abstract: Provided herein are compounds, such as compounds of Formula I, that bind to androgen receptors and/or modulate activity of androgen receptors. Also provided are methods for making and using such compounds. Also provided are compositions including such compounds and methods for making and using such compositions.

Abstract translation: 本文提供了结合雄激素受体和/或调节雄激素受体活性的化合物，例如式I化合物。 还提供了制备和使用这些化合物的方法。 还提供了包含这些化合物的组合物和用于制备和使用这些组合物的方法。

公开(公告)号：US20020183314A1

公开(公告)日：2002-12-05

申请号：US10080503

申请日：2002-02-22

Applicant: Ligand Pharmaceuticals Incorporated

Inventor： Robert I. Higuchi ,  Lin Zhi ,  Donald S. Karanewsky ,  Anthony W. Thompson ,  Thomas R. Caferro ,  Neelakandha S. Mani ,  Jyun-Hung Chen ,  Marquis L. Cummings ,  James P. Edwards ,  Mark E. Adams ,  Charlotte L.F. Deckhut

IPC: C07D471/02 ,  C07D491/02 ,  C07D498/02

CPC classification number: C07D498/04 ,  C07D498/14 ,  Y02P20/582

Abstract: Novel non-steroidal tricyclic quinolinone and tricyclic quinoline compounds and compositions that are agonists, partial agonists and/or antagonists for androgen receptors (AR), their preparation and their uses are described.

Abstract translation: 描述了新型非甾体三环喹啉酮和三环喹啉化合物以及作为雄激素受体（AR）的激动剂，部分激动剂和/或拮抗剂及其用途的组合物及其用途。

公开(公告)号：US11566041B2

公开(公告)日：2023-01-31

申请号：US17835828

申请日：2022-06-08

Applicant: Ligand Pharmaceuticals Incorporated

Inventor： Lin Zhi

IPC: C07H17/00 ,  A61K31/706 ,  A61P31/12

Abstract: Provided herein are nucleotide prodrug compounds, their preparation and their uses, such as treating diseases or conditions of a viral infection.

公开(公告)号：US20220204448A1

公开(公告)日：2022-06-30

申请号：US17604729

申请日：2020-04-16

Applicant: Ligand Pharmaceuticals Incorporated

Inventor： Lin Zhi ,  Henri Sasmor

IPC: C07D207/08

Abstract: Disclosed herein are methods of crystallizing the compound of Formula (I), as well as crystalline forms thereof. Crystalline forms of Formula (I) disclosed include crystalline Form C, crystalline Form E, and Crystalline form B.

公开(公告)号：US20210121422A1

公开(公告)日：2021-04-29

申请号：US16969521

申请日：2019-02-13

Applicant: LIGAND PHARMACEUTICALS INCORPORATED ,  METAVANT SCIENCES GMBH

Inventor： Lin Zhi ,  Ian Henderson ,  Joseph Kaloko ,  Martin Osterhout

IPC: A61K31/185 ,  C07C309/24 ,  A61K31/155 ,  A61K31/427 ,  A61K31/4439 ,  A61K38/28 ,  A61K38/31 ,  A61K31/7032 ,  A61K31/702 ,  A61K31/64 ,  A61K31/366 ,  A61K31/455 ,  A61K45/06 ,  C07C315/04 ,  C07C201/12 ,  C07C209/36 ,  C07C67/343 ,  C07C67/00 ,  C07C231/02 ,  C07C231/12 ,  C07C315/06

Abstract: Provided herein are solid state forms of compounds, including enantiomerically pure forms thereof, and pharmaceutically acceptable salts or co-crystals and prodrugs thereof which have glucagon receptor antagonist or inverse agonist activity. Further, provided herein are pharmaceutical compositions and methods of treating, preventing, ameliorating, delaying the time to onset or reducing the risk for the development or progression of at least one condition, disease, or disorder for which one or more glucagon receptor antagonist is indicated, including Type I and II diabetes, insulin resistance, hyperglycemia, ketoacidosis, or ketosis.

公开(公告)号：US20210040102A1

公开(公告)日：2021-02-11

申请号：US17071273

申请日：2020-10-15

Applicant: Ligand Pharmaceuticals Incorporated

Inventor： Lin Zhi

IPC: C07D487/04

Abstract: Compounds and methods in the fields of chemistry and medicine are disclosed. Some of the disclosed embodiments include compounds, compositions and methods of using imidazole-fused heterocycle amines. Some of the disclosed embodiments include imizazo-fused heterocycle compounds useful to treat leukemia and other hematopoietic disorders.

公开(公告)号：US20200339551A1

公开(公告)日：2020-10-29

申请号：US16960681

申请日：2019-01-08

Applicant: Ligand Pharmaceuticals Incorporated

Inventor： Lin Zhi

IPC: C07D405/14 ,  C07D405/06 ,  C07D239/42

Abstract: Disclosed herein are acetal and cyclic acetal compounds, compositions, their preparation, and their uses. Some embodiments relate to their use as liver-targeting compounds.

公开(公告)号：US20200216468A1

公开(公告)日：2020-07-09

申请号：US16735988

申请日：2020-01-07

Applicant: Ligand Pharmaceuticals Incorporated

Inventor： Koc-Kan Ho ,  David Diller ,  Jeffrey J. Letourneau ,  Brian F. McGuinness ,  Andrew G. Cole ,  David Rosen ,  Cornelis A. van Oeveren ,  Jason C. Pickens ,  Lin Zhi ,  Yixing Shen ,  Bijan Pedram

IPC: C07D513/04 ,  C07D471/04 ,  C07D417/14 ,  C07D417/12 ,  A61P37/00 ,  A61P29/00 ,  C07D277/60 ,  C07D277/42 ,  C07D269/02 ,  C07D235/02 ,  A61K31/4353 ,  A61K31/4168 ,  A61K31/407

Abstract: Compounds and methods in the fields of chemistry and medicine are disclosed. Some of the disclosed embodiments include compounds, compositions and methods of using heterocycle amines. Some of the disclosed embodiments include heterocycle amines useful to treat inflammatory disorders.

公开(公告)号：US20190388452A1

公开(公告)日：2019-12-26

申请号：US16557768

申请日：2019-08-30

Applicant: LIGAND PHARMACEUTICALS INCORPORATED

Inventor： Lin Zhi

IPC: A61K31/7072 ,  A61K9/00 ,  A61K31/661 ,  A61K31/6615 ,  A61K31/663 ,  A61K31/675

Abstract: Provided herein are prodrug compounds, their preparation and their uses, such as treating liver diseases or nonliver diseases via intervening in molecular pathways in the liver.

公开(公告)号：US20170247325A1

公开(公告)日：2017-08-31

申请号：US15590884

申请日：2017-05-09

Applicant: Ligand Pharmaceuticals Incorporated

Inventor： Lin Zhi

IPC: C07D207/09 ,  A61K45/06 ,  A61K31/5383 ,  A61K31/402 ,  C07D498/04

CPC classification number: C07D207/09 ,  A61K31/401 ,  A61K31/402 ,  A61K31/5383 ,  A61K45/06 ,  C07D207/08 ,  C07D207/16 ,  C07D498/04 ,  Y02A50/401

Abstract: Provided herein are compounds that bind to androgen receptors and/or modulate activity of androgen receptors. Also provided are methods for making and using such compounds. Also provided are compositions including such compounds and methods for making and using such compositions.